Myeloma 2016: Panel discussion on the status of genomics
Chng Wee Joo et al.
How to measure success in indolent disease? Endpoints, toxicity and more
Novel venetoclax combination therapy advancing the field of CLL
MRD assessment: NGS vs. flow cytometry
Novel ALL treatment strategies: inotuzumab ozogamicin